Press release
Pulmonary Sarcoidosis Pipeline Insights, Clinical Trials, Emerging Drugs and Companies 2024
Discover the latest drugs and treatment options in the Pulmonary Sarcoidosis Pipeline. Dive into DelveInsight's comprehensive report today! @ Pulmonary Sarcoidosis Pipeline Outlook [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Pulmonary Sarcoidosis Pipeline Report
* In October 2024:- Kinevant Sciences GmbH- A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis. Participants will be randomized to receive namilumab or placebo in the 26-week Double-blind Treatment Period of the study. Namilumab, or placebo, will be administered subcutaneously (SC) every 4 weeks through Week 22 after the initial dosing period.
* In September 2024:- Xentria Inc.- A Seamless, Phase 1b/2 Multiple Ascending Dose/Proof of Concept Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis With or Without Extrapulmonary Manifestations. A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
* In September 2024:- Bristol-Myers Squibb- A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
* DelveInsight's Pulmonary Sarcoidosis pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Pulmonary Sarcoidosis treatment.
* The leading Pulmonary Sarcoidosis Companies such as Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA , and others.
* Promising Pulmonary Sarcoidosis Therapies such as BMS-986278, Inhaled Treprostinil, Namilumab , and others
Stay ahead with the most recent pipeline outlook for Pulmonary Sarcoidosis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Pulmonary Sarcoidosis Treatment Drugs [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Sarcoidosis Emerging Drugs
* CMK 389: Novartis
CMK 389 acts as inhibitors of Interleukin 18. It is being developed by Novartis for Pulmonary sarcoidosis and is currently in phase II stage of development.
* ATYR1923: aTyr Pharma
ATYR1923 is a potential first-in-class, disease modifying therapy for patients with severe inflammatory lung diseases with high unmet medical need. ATYR1923 works by selectively modulating Neuropilin-2 (NRP2) to downregulate the innate and adaptive immune responses in uncontrolled inflammatory disease states to resolve inflammation and prevent subsequent fibrosis. ATYR1923 is conducting a Phase 1b/2a clinical trial in pulmonary sarcoidosis, a major form of interstitial lung disease (ILD), a group of immune-mediated disorders that cause progressive fibrosis of the lung.
Explore groundbreaking therapies and clinical trials in the Pulmonary Sarcoidosis Pipeline. Access DelveInsight's detailed report now! @ New Pulmonary Sarcoidosis Drugs [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Pulmonary Sarcoidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravaginal
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Pulmonary Sarcoidosis Products have been categorized under various Molecule types such as
* Vaccines
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Product Type
Unveil the future of Pulmonary Sarcoidosis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Pulmonary Sarcoidosis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Pulmonary Sarcoidosis Pipeline Report
* Coverage- Global
* Pulmonary Sarcoidosis Companies- Novartis, aTyr Pharma, Relief Therapeutics, AI Therapeutics, SarcoMed USA, and others.
* Pulmonary Sarcoidosis Therapies- BMS-986278, Inhaled Treprostinil, Namilumab, and others.
* Pulmonary Sarcoidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Pulmonary Sarcoidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Pulmonary Sarcoidosis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Pulmonary Sarcoidosis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/pulmonary-sarcoidosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Pulmonary Sarcoidosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Pulmonary Sarcoidosis- DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Pulmonary Sarcoidosis Collaboration Deals
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CMK389: Novartis
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* ATYR1923: aTyr Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* LAM-001: AI Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Pulmonary Sarcoidosis Key Companies
* Pulmonary Sarcoidosis Key Products
* Pulmonary Sarcoidosis- Unmet Needs
* Pulmonary Sarcoidosis- Market Drivers and Barriers
* Pulmonary Sarcoidosis- Future Perspectives and Conclusion
* Pulmonary Sarcoidosis Analyst Views
* Pulmonary Sarcoidosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-sarcoidosis-pipeline-insights-clinical-trials-emerging-drugs-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Sarcoidosis Pipeline Insights, Clinical Trials, Emerging Drugs and Companies 2024 here
News-ID: 3681110 • Views: …
More Releases from ABNewswire
Couples Therapy Birmingham Support in Birmingham Expanded by Phinity Therapy to …
Couples Therapy Birmingham services have expanded across Frankley, Northfield, and Halesowen, improving access to professional relationship counselling for local residents. Phinity Therapy provides structured and confidential support for couples seeking guidance with communication challenges, conflict resolution, and long-term relationship wellbeing throughout the Birmingham region.
Introduction: Couples Therapy Birmingham in Birmingham
Couples Therapy Birmingham services are becoming more accessible to residents across Birmingham following the expansion of structured relationship support into Frankley, Northfield,…
UK Taxpayers Seek Easy Tax Software as Digital Filing Becomes the New Normal
As digital tax filing becomes the default across the UK, taxpayers are increasingly searching for easy tax software that removes complexity from self assessment and online submissions. With more people managing freelance income, property earnings, and side work alongside PAYE employment, demand for simpler tools is rising. Industry data from Pie shows sustained growth in users choosing guided, app-based tax platforms over manual forms and spreadsheets.
LONDON, United Kingdom - February…
Top CPA in Dallas, Texas, Advises Clients to Prepare for Potential Shifts in Tax …
Dallas, TX - With comprehensive tax reform proposals under consideration, taxpayers and business owners face a landscape of potential changes that could reshape financial strategies for years to come. The proposals encompass wide-ranging modifications to individual deductions, capital gains treatment, estate tax exemptions, and business tax structures that require proactive planning and careful evaluation.
Jeff Badu, a well-known tax accountant in Dallas, Texas [https://www.abnewswire.com/pressreleases/tax-professional-in-dallas-tx-highlights-importance-of-early-retirement-planning-as-many-approach-retirement-unprepared_785667.html], advises clients to review their current tax…
Top Plant Maintenance Contractor in Bay Area CA Notes Wave of Office Relocations …
Bay Area, CA - As commercial lease expirations accelerate through 2026, businesses across Silicon Valley are rethinking their office strategies. Companies are downsizing while simultaneously upgrading to class A office spaces featuring biophilic design elements that integrate nature into the workplace. This shift reflects a strategic response to the hybrid work era, where premium environments can make the difference in bringing employees back to the office.
Jennifer Farmer, a plant maintenance…
More Releases for Pulmonary
Innovation In Pulmonary Drug Delivery Devices Industry Trends Gaining Momentum i …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pulmonary Drug Delivery Devices Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pulmonary drug delivery devices has experienced significant growth in the past few years. The market is projected to increase from $49.52 billion in 2024 to $52.8 billion in 2025,…
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
